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Abstract
Purpose Thrombocytosis associated with poorer prognoses
seems to be a frequent preoperative finding in different kind
of cancers. The aim of the present study was to evaluate
whether thrombocytosis can be used as a prognostic marker
for oral squamous cell carcinoma (SCC).
Methods Altogether, 288 patients with oral SCC were
considered, as well as all platelet counts between 1 and 5 days
prior to surgical treatment, recurrence rate, and lymph node
metastasis. The minimum follow-up time was 12 months.
Results The mean preoperative thrombocyte score of the
patients who received surgery was 259.55±83.8 Tsd/μl; 273
out of 288 patients were in the normal thrombocyte range, and
12 had a thrombocytosis. From 51 patients with recurrence,
three were in the thrombocytosis group, and 45 patients with
recurrence were in the normal thrombocyte range.
Conclusion The present results do not confirm that throm-
bocytosis can be seen as marker for poor tumor prognosis.
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Introduction
The 5-year survival rate for oral squamous cell carcinoma
(SCC) has been virtually unchanged over the past few
decades. Several prognostic factors—like infiltration depth,
metastases, and perineural infiltration [1]—are well known.
Concerning the markers in the routine laboratory test for
oral SCC, a few studies have been performed concerning
CRP [2] and haemoglobin [3]. Thrombocytosis, which is an
abnormally high number of platelets in the circulating
blood, in association with malignancies was described by
Riess in 1872 [4]. More recently several studies have
reported thrombocytosis as associated with renal [5],
colorectal [6], endometrial [7], breast [8], gastric [9], lung
[10], and esophageal cancers [11]. However, for oral SCC
only one study, to the authors‘ knowledge, has reported an
association for oral cancer [12] in 253 patients with a
poorer survival rate, aggressive tumor growth, lymph node
metastases, and distant metastases.
Therefore, the aim of the current study was to evaluate
the prevalence of thrombocytosis and its association with
recurrence and metastases rates.
Patients and methods
A total of 311 patients who were treated for oral SCC
between 1999 and 2008 at a single center (Department of
Craniomaxillofacial and Oral Surgery, University Hospital,
Zurich) were evaluated retrospectively. All platelet counts
between 1 and 5 days prior to surgical treatment, recurrence
rate, and lymph node metastasis were taken into consider-
ation. An Excel database was used for evaluation. The
minimum follow-up time was 12 months. Exclusion criteria
were inadequate information, a follow-up time of less than
12 months, autoimmune disease, acute inflammatory
disease, and haemodialysis. Therefore, two male patients
were excluded: one due to Fanconi Anemia and the other
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because of a graft-versus-host disease after stem cell
transplantation.
In agreement with other studies [13, 14], we defined a
thrombocytosis as >400,000 thrombocytes/μl.
Results
Between 1998 and 2008, oral cancer was detected in 309
patients in the Department of Cranio-Maxillo-Facial Surgery
of the University Hospital in Zurich. Of these patients, 21
(6.8%) were treated with primary radiotherapy. The other 288
patients (93.2%) received surgery with or without radiother-
apy/chemotherapy.
The mean preoperative thrombocyte score of the
patients who received surgery was 259.55±83.8 Tsd/μl.
In 273 patients (94.8%), the preoperative score was under
400 Tsd/μl, and in 259 patients (89.9%) the score was in
the normal range between 150 and 400 Tsd/μl. Twelve
patients (4.2%) had an elevated thrombocyte score over
400 Tsd/μl, and no preoperative score was documented for
three patients (1%) (Fig. 1).
Local recurrence was seen in 51 patients (17.7%) after a
mean time of 23.73±23.78 months (range 1–89 months). The
occurrence of second tumors was seen in 21 patients (7.3%)
after a mean time of 27.71±18.17 months (range 4–
87 months). No recurrence or occurrence of second tumors
was seen in 216 patients (75%). Cervical lymph node
metastases were observed in 45 patients (15.6%) after a mean
time of 16.71±23.09 months (range 1–93months), and distant
metastases were detected in 19 patients (6.6%) after a mean
time of 23±24.45 months (range 2–111 months). No
metastases were found in 224 patients (77.8%).
A local recurrence was observed in 48 patients (94.1%)
in the normal range group and in three patients (5.9%) in
the group with elevated preoperative Tc scores. No
correlation was found between tumor recurrence and the
preoperative Tc score. All 17 patients who developed a
second tumor had a normal preoperative Tc score. Nor were
preoperative thrombocyte counts (Table 1) found to relate
time elapsed before recurrence (Fig. 2) or before metastases
(Fig. 3). All 45 patients with lymph node metastases were
in the group with a normal Tc score.
Discussion
Thrombocytosis associated with poorer prognoses has seemed
to be a frequent preoperative finding in different kind of
cancers, and the development of thrombi accompanying
cancer cells has been well studied. However, our study did
not support the notion that thrombocytosis is associated with a
Table 1 Overview of the studied patient
150,000–400,000
(Normal range)
>400,000
Elevated group)
Patients 273 patients 12 patients
Recurrence 48 patients 3 patients
Metastases 45 patients 0 patients
Second tumor 17 patients 4 patients
Fig. 1 Overview of the
thrombocyte count in the
patients studied
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higher recurrence and metastases rate. One reason could be
that most oral cancer metastasis occurs by lymphatic spread
instead of through hematologic spread, and platelets appear to
contribute to metastasis haematologically spread by their
adhesive interaction with tumor cells via the adhesive proteins
fibronectin and von Willebrand factor [15]. The ability of
some tumor cells to aggregate platelets in vitro and their
metastatic potential in vivo is well known [16]. It would be
of interest to investigate whether oral SCC cell lines do have
this ability. Therefore, further investigation is still needed.
In the present study, thrombocytosis was found in 4.2%
patients with oral SCC. This is considerably lower than the
results (61 out of 253 patients/24.1%) reported by Lu et al.
[12]. Lu et al. [12] proposed that preoperative thrombocy-
tosis could be associated with a larger tumor burden or a
later stage, both of which adversely affect survival. The
Fig. 2 Time to recurrence
Fig. 3 Time to metastases
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prevalence reported in studies of other malignancies ranged
from 4.5% [17] to 25% [18].
The pathophysiology underlying the reactive thrombocy-
tosis in patients with malignoma has yet not been fully
elucidated. An increase of tumor-related humoral factors
leading to an increased production of platelet, as well as
tumor-derived factors with thrombopoietin-like activity and
growth factors in addition to growth factors released by
megakaryocytes, are believed to influence this process [19,
20]. In inflammatory conditions, a stimulation of interleukin-
6 (IL-6), a potent stimulator of megakaryocytopoiesis,
leading to increased thrombopoietin has been reported [21].
It is also unclear whether thrombocytosis is a result of
growth factors secreted by tumor cells and the host response,
or an event that directly worsens the prognosis [17]. The
other question that still has not been solved is whether
hypoxy plays a stimulating role in thrombocytes, as it does
in erythrocytes [22]. Vascular endothelial growth factor
(VEGF), known to be increased in hypoxic tissue, is also
released by platelets on activation, and VEGF seems to
correlate with the platelet count [23], leading also to an
increased number of blood vessels in tumors.
These data, which are limited by the retrospective nature
of the study, do not confirm a causal relationship between
tumor aggressiveness and thrombocytosis.
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